Dr. Leslie of the Mayo Clinic Proves Spinal Decompression to be Up to 88.9% Effective for NECK and BACK PAIN!



PILOT: Effectiveness and Safety of Non-Surgical Spinal Decompression

ABSTRACT

OBJECTIVE: Prospective, multicenter, phase II, non-randomized, clinical study to evaluate the effectiveness and safety of the Axiom Worldwide DRX9000™ for active treatment of chronic LBP utilizing a standardized clinical research multimodal protocol.

METHODS: 20 patients with chronic LBP based on a diagnosis of musculoskeletal or mechanical LBP, herniated discs, bulging or protruding discs, degenerative disc, pain from failed back surgery more than 6 months previously, posterior facet syndrome or sciatica underwent a series of 20 DRX™ treatments (28 mins each) for 6 weeks with 5 sessions the first week tapering to 1 session/wk. Treatment multimodal protocol included ice after DRX™ sessions, lumbar stretching exercises, and adjunct analgesics as required. Assessments of pain, analgesic use, functionality, satisfaction, activities of daily living and safety were collected through examinations, questionnaires and patient diaries.

RESULTS: 18 evaluable subjects (33.3% female, 83.3% white, mean age 46.6, 77.8% employed) had mean pain score 6.4 on a 0 to 10 scale (0=no pain 10=worst pain) prior to first DRX™ treatment that decreased to 0.8 after last DRX™ treatment. 88.9% of patients (16 out of 18) reported an improvement in back pain, and better function as measured by activities of daily living. On a 0 to 10 scale (0=Not satisfied 10=Very satisfied) patients rated the DRX9000 an 8.1. No patient required any invasive therapies (e.g., epidural injections, surgery).

CONCLUSION: Overall, patients' pain improved after DRX™ treatment, requiring fewer analgesics, with better function. There were no safety issues identified with the multimodal treatment routine. Non-treatment or control groups were not included making efficacy outcome versus placebo or spontaneous recovery difficult to determine. Randomized double-blinded or comparative long-term outcome trials are needed to further prove the efficacy of the DRX9000™ non-surgical spinal decompression system for the routine treatment of chronic LBP.

BACKGROUND

- decompression over other non-surgical treatments

- Efficacy versus placebo or spontaneous recovery difficult to determine


MATERIALS AND METHODS

METHODS

- Prospective, multi-center, phase II, non-randomized clinical trial
- 3 free-standing clinics (2 MDs and 1 DC)
- Diagnosis: Low back pain > 12 weeks
- · Outcome measures assessed:
 - Daily Pain Diary
 - Verbal Rating Scale (VRS)
 - Oswestry Pain Questionnaire
 - Adverse Events
 - Satisfaction Survey

TREATMENT PROTOCOL

- DRX9000™ sessions
 - 28-minute sessions for 6 weeks
 - Total of 20 treatments
 - 5 sessions week 1 & 2
 - 3 sessions week 3 & 4
 - 2 sessions week 5 & 6
- Additional Therapy
 - Ice therapy post DRX™



23.7

25

20

15

10

*p+.001 **p<.000

CHANGE IN OSWESTRY SCORES

CHANGE IN PAIN SCORE BY TREATMENT WEEK

- - Back exercises after week 2

RESULTS

Procedure

Chiropractic

Stimulation

ice Therapy

Massage

Therapy

Exercise

Physical

Therapy

Heat

Muscle

DEMOGRAPHICS Total Number of Subjects = 18 Male Mean Age 46.6 yrs LBP Symptom Duration (mean) 526 Mean Height 175 cm weeks Employed 77.8% Mean Weight 102 kg Retired 16.6% White 83.3% Other 5.6% Hispanic 16.7%

FAILED THERAPY PRIOR TO DRX9000™

16

10

6

5

5

Procedure

Acupuncture

Epidural

Injections

Ultrasound

Other Decom-

pressive Therapy

Lumbar support

Facet Injections

5

3

3

3

1

1

1

TENS

DIAGNOSIS		LOCATION	
Bulging/Protruding Disc	15	L1-L2	1
Degenerative Disc	8	L2-L3	3
Herniated Disc	6	L3-L4	4
Posterior Facet Syndrome	2	L4-L5	14
Failed Back Surgery	1	LS-S1	12

RESULTS

*p<.0001						
SATISFACTION SURVEY						
Satisfaction by Week		Would you recommend DRX9000™ to anyone else?				
Week 3 7.6	Week 6 8.1	Yes 88.9%	No 11.1%			

DA		INID

- Paucity of literature on benefits of non-surgical spinal
- Previous studies are poorly designed
- Results are descriptive in nature
- Over 1,200 DRX9000™ in use today

ADVERSE EVENTS

Adverse Event	Related to device	Adverse Event	Related to device
Neck Pain	Possibly	Shoulder Pain	No
Head Cold (2)	No	LBP/flu-like symptoms	No
Sinus headache (2)	No	Vertigo	No
Sinus infection No		Adrenal Insufficiency	No

Disclaimer: This study was funded by Axiom Worldwide, LLC.

CONCLUSION

- A 6-week course of 20 DRX9000™ treatments significantly reduced the severity of chronic LBP in 89% (16 of 18) of treated patients from 6.4 to 3.1 after 2 weeks and to only 0.8 (scale 0-10) after completion of treatment
- Oswestry Disability scores improved from 23.7 to only 5.5 at end of therapy
- Adjunctive pain medication consumption was decreased by DRX9000™ treatments
- No significant adverse events or safety issues resulted from DRX9000™ treatments
- The DRX9000™ shows great promise in treating chronic LBP arising from multiple causes
- Comparative outcome trials utilizing a set of standardized and validated multiple outcome variables, as was utilized in this study, are being planned to document the value of DRX9000™ non-surgical spinal decompression system in routine treatment of chronic LBP

SUMMARY of PILOT STUDY

Conducted by: Mayo Clinic Supervised by: John Leslie, M.D.

Subjects Conditions

- Herniated Discs
- Bulging Discs
- Degenerative Discs
- Failed Back Surgery
- Facet Syndrome

Prior to Treatment

- Average Pain Score 6.4 Out of 10
- Pain Greater Than 6 Months


6 Week Treatment Protocol

20 Treatments

Post Treatment

- Average Pain Decreased to 0.8 Out of 10
- Decreased Pain
- Improved Function
- Required Fewed Analgesics After Treatment
- No Safety Issues or Adverse Effects





Presented At:

American Academy of Pain Management

AAPM 18th Annual Clinical Meeting
Sept. 27-30, 2007 | Las Vegas, NV

New York State Society of Anesthesiologists
61st Post Graduate Assembly in Anesthesiol
Dec. 7-11, 2007 | New York, NY 61st Post Graduate Assembly in Anesthesiology Dec. 7-11, 2007 | New York, NY

American Conference in Pain Medicine Parker Seminar April 4-5, 2008 New York, NY

Feb. 7-9, 2008 | Las Vegas, NV

Study Team:
John Leslie, MD', Charlotte Richmond, PhD', Alex Macario, MD', Christian Apfel, MD', Frank Florio, DC', Darren Clair, MD', Martin Auster, MD', Joseph Perfolizzi, MD¹²